Skip to content

Onconova Therapeutics (NASDAQ: ONTX) Reduced to Hold at Zacks Investment Research

NASDAQ: ONTX was reduced by  Zacks Research  from a “purchase” score to a “hold” ranking in a research note issued to financiers on Thursday, reports.

According to Zacks, “Onconova Therapeutics, Inc. runs as a clinical-stage biopharmaceutical business. It concentrates on finding as well as establishing tiny molecule drug prospects to deal with cancer. The Firm‘s items under different stages of growth include Rigosertib intravenous (IV), Rigosertib Oral, Rigosertib IV, ON 013105 as well as Recilisib. Onconova Therapeutics, Inc. is headquartered in Newtown, Pennsylvania. “

Several other equities research experts additionally just recently discussed the firm. Noble Financial editioned a “purchase” score as well as issued a $11.00 price purpose on shares of Onconova Therapeutics in a report on Thursday, September 23rd. Guggenheim dropped their rate target on Onconova Therapeutics from $29.00 to $12.00 as well as established a “purchase” ranking on the stock in a research note on Tuesday, September 28th.

NASDAQ: ONTX opened at $2.25 on Thursday. Onconova Therapeutics has a twelve month low of $2.22 and also a twelve month high of $28.95. Business has a 50 day moving average price of $2.90 as well as a two-hundred day relocating typical rate of $4.16. The company has a market cap of $46.76 million, a P/E ratio of -1.82 and a beta of 1.67.

Onconova Therapeutics (NASDAQ: ONTX) last released its quarterly profits outcomes on Thursday, November 11th. The biopharmaceutical firm reported ($ 0.22) profits per share for the quarter, covering analysts’ consensus quotes of ($ 0.33) by $0.11. Onconova Therapeutics had an unfavorable return on equity of 59.78% as well as an unfavorable net margin of 8,294.27%. The firm had income of $0.06 million during the quarter, compared to the agreement estimate of $0.06 million. Throughout the exact same quarter in the prior year, the firm posted ($ 0.45) EPS. As a group, research analysts anticipate that Onconova Therapeutics will certainly post -1.18 EPS for the existing year.

A number of hedge funds have actually lately bought and sold shares of ONTX. GSA Resources Partners LLP purchased a brand-new position in Onconova Therapeutics during the 3rd quarter worth $922,000. Hudson Bay Resources Monitoring LP acquired a new placement in shares of Onconova Therapeutics in the 3rd quarter worth $635,000. Pura Vida Investments LLC bought a brand-new position in shares of Onconova Therapeutics in the 3rd quarter worth $575,000. CVI Holdings LLC bought a brand-new position in shares of Onconova Therapeutics in the 3rd quarter worth $493,000. Finally, Dimensional Fund Advisors LP acquired a brand-new placement in shares of Onconova Therapeutics in the 2nd quarter worth $509,000. Hedge funds and also other institutional capitalists have 13.36% of the firm’s stock.

Concerning Onconova Therapeutics

Onconova Therapeutics, Inc is a clinical-stage biopharmaceutical firm, which participates in the identification and also growth of oncology therapeutics. It focuses on discovering and creating little molecule medication prospects to treat cancer. The firm was founded by Ramesh Kumar and E. Premkumar Reddy on December 22, 1998 and is headquartered in Newtown, PA

. Obtain a free duplicate of the Zacks research record on Onconova Therapeutics (ONTX).

For more details about research offerings from Zacks Investment Research, go to

This immediate news alert was produced by narrative science modern technology and also economic data from Market in order to supply visitors with the fastest as well as most accurate coverage. This tale was evaluated by Market’s content team before publication. 



Before you take into consideration Onconova Therapeutics, you’ll intend to hear this.

Market keeps track of Wall Street’s premier as well as finest performing research analysts and also the stocks they suggest to their customers daily. Market has recognized the five stocks that cover analysts are silently murmuring to their clients to get currently prior to the broader market catches on … and also Onconova Therapeutics had not been on the list.

While Onconova Therapeutics currently has a “Buy” rating among experts, top-rated experts believe these five stocks are better buys.